Abliva | BioStock Life Science Summit 2024

(15:5)

Abliva | BioStock Global Forum 2024

(15:15)

Abliva leads the way with potential mitochondrial disease treatment

(12:12)

BioStock | Abliva on the phase II-study | March 2023

(5:40)

BioStock Investor Meeting | Abliva | March 2023

(18:36)

BioStock | NLSDays | Abliva

(1:31)

BioStock | Abliva | Financing round | June 2022

(6:16)

BioStock Life Science Fall Summit | Abliva | October 2023

(13:37)

BioStock Life Science Summit 2021 | Abliva

(22:26)

Will they get FDA Approval? A Better Leukemia Treatment - Autolus Therapeutics - AUTL Stock

(20:57)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

Abarceo Pharma | Investing in Life Science 2024

(12:48)

IRLAB Therapeutics | Investing in Life Science 2024

(15:32)

BioStock Global Forum 2024 – May 30, Part II

(2:39:5)

Trading Direkt 2023-01-10 | Aktieprofilen Joakim Bornold \

(43:55)

Abarceo Pharma | INTERVIEW | Investing in Life Science 2024

(6:25)

BioStock Life Science Fall Summit | Day 1 Session 1 | October 2023

(1:10:15)

Top 10 Sales Tactics in Healthcare

(8:16)

BioStock Life Science Fall Summit | Aqilion | October 2023

(14:27)

Abliva | BioStock Life Science Summit 2020

(16:19)

Abliva - CEO Ellen Donnelly talks about the positive interim analysis in the FALCON study

(3:24)

BioStock Live | Abliva March 9 2021

(19:7)

Abliva - A Patient-Centric Approach to Drug Development - World Mitochondrial Disease Week 2022

(3:47)

Abliva - Introducing the FALCON study - World Mitochondrial Disease Week

(2:31)

Abliva - Participating in the FALCON Study - World Mitochondrial Disease Week 2023

(2:20)

Abliva - About Lead Candidate KL1333

(2:16)

Abliva - Primary Mitochondrial Disease and NAD+/NADH

(3:46)

Abliva - Drug Development - Mito Disease

(3:41)

Abliva - Abliva’s upcoming Phase 2/3 study with KL1333 - World Mitochondrial Disease Week 2022

(3:43)